Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16198628 | 0.85 | HPGD (0.49) | ALDH1A1MGLLKMT2AL3MBTL1LMNA | |
| SCHEMBL18994202 | 0.83 | LMNA (0.44) | ALDH1A1ADORA3NPC1RAB9AMAPK14 | |
| SCHEMBL9966144 | 0.82 | ALDH1A1 (0.44) | ALDH1A1ADORA3RAB9AHSP90AA1KMT2A | |
| SCHEMBL7652832 | 0.77 | RPA1 (0.51) | ALDH1A1ADORA3NPBWR1MCHR1NPC1 | |
| SCHEMBL10439124 | 0.74 | NPC1 (0.55) | ALDH1A1ADORA3NPBWR1MCHR1NPC1 | |
| SCHEMBL29001505 | 0.73 | CTSK (0.43) | RIPK2ALDH1A1ADORA3NPBWR1MCHR1 | |
| SCHEMBL5905967 | 0.70 | CYP1A2 (0.48) | ALDH1A1ADORA3NPBWR1MCHR1NPC1 | |
| SCHEMBL8775840 | 0.70 | NPC1 (0.54) | ALDH1A1ADORA3NPBWR1MCHR1NPC1 | |
| SCHEMBL16788814 | 0.70 | MAPK14 (0.55) | RIPK2ALDH1A1MAPK14MAPK13MAPK12 | |
| SCHEMBL23401692 | 0.69 | MAPK14 (0.57) | RIPK2ALDH1A1MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981999-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-21 | — | — | US | disclosed |
| US-9683002-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-31 | — | — | US | disclosed |
| US-9045443-B2 | Nitric oxide donor neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-06-02 | — | — | US | disclosed |
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-30 | — | — | US | disclosed |
| US-8871792-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119571-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RIPK2 3409/4885ALDH1A1 2394/4885ADORA3 744/4885 |
| US-20160090393-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RIPK2 3409/4885ALDH1A1 2394/4885ADORA3 744/4885 |
| US-20170362260-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | RIPK2 3409/4885ALDH1A1 2394/4885ADORA3 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.